Real-world first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer: the CAPSTAN CRC study.

ESMO Open · 2022 · PMC9832736 · PMID 36368253

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

31 The recent phase II FIRE-4.5 study, which assessed FOLFOXIRI plus bevacizumab versus FOLFOXIRI plus cetuximab as first-line treatment for BRAF V600E -mutant mCRC, showed a trend toward improved survival with bevacizumab in patients with right-sided tumors. 20 This further supports the use of bevacizumab in combination with chemotherapy in the first-line setting for these patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.